PL2247294T3 - Makrolidy do leczenia chorób przez hamowanie PDE - Google Patents

Makrolidy do leczenia chorób przez hamowanie PDE

Info

Publication number
PL2247294T3
PL2247294T3 PL09707590T PL09707590T PL2247294T3 PL 2247294 T3 PL2247294 T3 PL 2247294T3 PL 09707590 T PL09707590 T PL 09707590T PL 09707590 T PL09707590 T PL 09707590T PL 2247294 T3 PL2247294 T3 PL 2247294T3
Authority
PL
Poland
Prior art keywords
macrolides
treating diseases
diseases mediated
pde inhibition
pde
Prior art date
Application number
PL09707590T
Other languages
English (en)
Inventor
Johannes Laurenz Kellenberger
Jürg Dreier
Stefan Bernhard Reinelt
Original Assignee
Basilea Pharmaceutica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basilea Pharmaceutica Ag filed Critical Basilea Pharmaceutica Ag
Publication of PL2247294T3 publication Critical patent/PL2247294T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL09707590T 2008-02-08 2009-02-09 Makrolidy do leczenia chorób przez hamowanie PDE PL2247294T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08101444 2008-02-08
PCT/EP2009/051457 WO2009098320A2 (en) 2008-02-08 2009-02-09 Macrolides and uses of macrolides
EP09707590.7A EP2247294B1 (en) 2008-02-08 2009-02-09 Macrolides for treating diseases mediated through pde inhibition

Publications (1)

Publication Number Publication Date
PL2247294T3 true PL2247294T3 (pl) 2014-09-30

Family

ID=39595658

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09707590T PL2247294T3 (pl) 2008-02-08 2009-02-09 Makrolidy do leczenia chorób przez hamowanie PDE

Country Status (13)

Country Link
US (1) US8445451B2 (pl)
EP (1) EP2247294B1 (pl)
JP (1) JP5769972B2 (pl)
KR (1) KR101589960B1 (pl)
CN (2) CN103142632B (pl)
AU (1) AU2009211333B2 (pl)
CA (1) CA2714389C (pl)
ES (1) ES2474697T3 (pl)
MX (1) MX2010008751A (pl)
PL (1) PL2247294T3 (pl)
PT (1) PT2247294E (pl)
WO (1) WO2009098320A2 (pl)
ZA (1) ZA201005515B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201200518A (en) * 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
US8859550B2 (en) 2011-09-12 2014-10-14 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
ES2607638T3 (es) * 2012-12-31 2017-04-03 Basilea Pharmaceutica Ag Macrólidos seleccionados con actividad inhibidora de PDE4
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0639644A1 (de) * 1993-08-16 1995-02-22 Ciba-Geigy Ag Neue Makrolide und ihre Verwendung
KR20020007374A (ko) * 1999-04-16 2002-01-26 추후제출 매크롤라이드 항감염제
EP1439186A3 (en) 1999-12-29 2004-11-03 Pfizer Products Inc. Intermediates for novel antibacterial and prokinetic macrolides
KR100502031B1 (ko) * 2000-08-22 2005-07-25 바실리어 파마슈티카 아게 항균 활성을 갖는 신규한 매크롤라이드
US6995143B2 (en) * 2002-02-28 2006-02-07 Basilea Pharmaceutica Ag Macrolides with antibacterial activity
US6727229B2 (en) * 2002-08-19 2004-04-27 Enanta Pharmaceuticals, Inc. 11,12-substituted lactone ketolide derivatives having antibacterial activity
US6720308B1 (en) * 2002-11-07 2004-04-13 Enanta Pharmaceuticals, Inc. Anhydrolide derivatives having antibacterial activity
US7414030B2 (en) * 2004-01-07 2008-08-19 Enanta Pharmaceuticals, Inc. 6-11 Bicyclic erythromycin derivatives
ATE427315T1 (de) * 2005-02-09 2009-04-15 Basilea Pharmaceutica Ag Neue makrolide
WO2008017696A1 (en) * 2006-08-09 2008-02-14 Basilea Pharmaceutica Ag New macrolides useful against inflammatory and allergic disseases
CA2713776C (en) 2008-02-08 2018-06-05 Basilea Pharmaceutica Ag Macrolides as pde4 inhibitors

Also Published As

Publication number Publication date
PT2247294E (pt) 2014-07-10
US20110021449A1 (en) 2011-01-27
US8445451B2 (en) 2013-05-21
KR101589960B1 (ko) 2016-01-29
EP2247294A2 (en) 2010-11-10
CN103142632A (zh) 2013-06-12
MX2010008751A (es) 2010-08-31
CN101939012B (zh) 2015-04-22
EP2247294B1 (en) 2014-03-26
AU2009211333B2 (en) 2013-10-03
JP5769972B2 (ja) 2015-08-26
CN103142632B (zh) 2016-01-20
ZA201005515B (en) 2011-04-28
WO2009098320A3 (en) 2009-11-19
JP2011511044A (ja) 2011-04-07
CA2714389C (en) 2016-10-18
WO2009098320A2 (en) 2009-08-13
AU2009211333A1 (en) 2009-08-13
CA2714389A1 (en) 2009-08-13
ES2474697T3 (es) 2014-07-09
CN101939012A (zh) 2011-01-05
KR20100112642A (ko) 2010-10-19

Similar Documents

Publication Publication Date Title
PT2252148T (pt) Métodos de tratamento da síndrome do intestino irritável
IL229878A0 (en) Compounds for the treatment of cancer
IL238338A0 (en) Processes for preparing sglt2 inhibitors
IL215767A0 (en) Methods of treatment for solid tumors
ZA201109031B (en) Compounds useful for treating aids
ZA201101202B (en) Methods for inhibiting ocular angiogenesis
IL234149A0 (en) Use of olipristal acetate to treat uterine fibroids
ZA201203449B (en) Sulfoxide derivatives for treating tumors
IL213398A0 (en) Compounds for treating cancer
ZA201005515B (en) Macrolides for treating diseases mediated through pde inhibition
IL213287A0 (en) Treatment for glomerulonephritis
WO2010083208A9 (en) Treating neuropsychiatric diseases
EP2211871A4 (en) METHOD FOR INHIBITING ANGIOGENESIS OR TREATING CANCER
EP2039392A4 (en) DEVICE FOR PHYSIOTHERAPY TREATMENT OF DISEASES OF VARIOUS AITIOLOGIES
ZA201201894B (en) Pharmaceutical combination for treating tumor
ZA201201740B (en) Process for the preparation of cathepsin s inhibitors
PL384259A1 (pl) Kompozycja farmaceutyczna do leczenia chorób skórnych
GB0818713D0 (en) Substances useful for treating diseases
GB0914322D0 (en) Compounds for treating cancer
PL389570A1 (pl) Urządzenie do gry losowej
GB0805119D0 (en) Treatment of myelination diseases
GB0904314D0 (en) Anti-thrombotic therapy
GB0913427D0 (en) Compounds for treatment of imflammation